Toxic Encephalopathy and Delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism

J. Müller, Judit Kralovánszky, Vilmos Adleff, Éva Pap, Krisztina Németh, Viktor Komlósi, Gábor Kovács

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: High-dose methotrexate (HD-MTX) is one of the most important agents in the therapy of osteosarcoma (OSC). Acute and delayed toxicities still constitute clinical problems. Methylenetetrahydrofolate reductase (MTHFR) has a key role in the folate cycle. In case of homozygosity of the 677C-→T polymorphism, treatment with antimetabolites, such as MTX, can cause additional toxicity. Case Report: In the present work, we describe the case of a 10-year-old boy with OSC. After the first HD-MTX infusion (12 g/m2/6 h) acute neurological disturbances were detected followed by severe hepatotoxicity. Plasma concentrations of MTX and 7-OH-MTX showed delayed clearance. Calcium folinate was administered to the patient until +186 hours. Tha patient was homozygous for the 677 polymorphism and wild-type for the 1298 polymorphism of the MTHFR gene. Conclusion: We hypothesize that MTX toxicity can be explained by the association between homozygosity of the MTHFR C677T polymorphism causing disturbances in the folate status and thus an enhanced vulnerability of the central nervous system to antimetabolites and to the prolonged MTX exposure due to delayed MTX clearance.

Original languageEnglish
Pages (from-to)3051-3054
Number of pages4
JournalAnticancer Research
Volume28
Issue number5 B
Publication statusPublished - Sep 2008

Fingerprint

Neurotoxicity Syndromes
Methylenetetrahydrofolate Reductase (NADPH2)
Methotrexate
Antimetabolites
Osteosarcoma
Folic Acid
Leucovorin
Therapeutics
Central Nervous System
Genes

Keywords

  • Methotrexate
  • MTHFR
  • Osteosarcoma
  • Polymorphism
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Müller, J., Kralovánszky, J., Adleff, V., Pap, É., Németh, K., Komlósi, V., & Kovács, G. (2008). Toxic Encephalopathy and Delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. Anticancer Research, 28(5 B), 3051-3054.

Toxic Encephalopathy and Delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. / Müller, J.; Kralovánszky, Judit; Adleff, Vilmos; Pap, Éva; Németh, Krisztina; Komlósi, Viktor; Kovács, Gábor.

In: Anticancer Research, Vol. 28, No. 5 B, 09.2008, p. 3051-3054.

Research output: Contribution to journalArticle

Müller, J, Kralovánszky, J, Adleff, V, Pap, É, Németh, K, Komlósi, V & Kovács, G 2008, 'Toxic Encephalopathy and Delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism', Anticancer Research, vol. 28, no. 5 B, pp. 3051-3054.
Müller, J. ; Kralovánszky, Judit ; Adleff, Vilmos ; Pap, Éva ; Németh, Krisztina ; Komlósi, Viktor ; Kovács, Gábor. / Toxic Encephalopathy and Delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. In: Anticancer Research. 2008 ; Vol. 28, No. 5 B. pp. 3051-3054.
@article{48a69fdb8ef84185a902524e28da457d,
title = "Toxic Encephalopathy and Delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism",
abstract = "Background: High-dose methotrexate (HD-MTX) is one of the most important agents in the therapy of osteosarcoma (OSC). Acute and delayed toxicities still constitute clinical problems. Methylenetetrahydrofolate reductase (MTHFR) has a key role in the folate cycle. In case of homozygosity of the 677C-→T polymorphism, treatment with antimetabolites, such as MTX, can cause additional toxicity. Case Report: In the present work, we describe the case of a 10-year-old boy with OSC. After the first HD-MTX infusion (12 g/m2/6 h) acute neurological disturbances were detected followed by severe hepatotoxicity. Plasma concentrations of MTX and 7-OH-MTX showed delayed clearance. Calcium folinate was administered to the patient until +186 hours. Tha patient was homozygous for the 677 polymorphism and wild-type for the 1298 polymorphism of the MTHFR gene. Conclusion: We hypothesize that MTX toxicity can be explained by the association between homozygosity of the MTHFR C677T polymorphism causing disturbances in the folate status and thus an enhanced vulnerability of the central nervous system to antimetabolites and to the prolonged MTX exposure due to delayed MTX clearance.",
keywords = "Methotrexate, MTHFR, Osteosarcoma, Polymorphism, Toxicity",
author = "J. M{\"u}ller and Judit Kralov{\'a}nszky and Vilmos Adleff and {\'E}va Pap and Krisztina N{\'e}meth and Viktor Koml{\'o}si and G{\'a}bor Kov{\'a}cs",
year = "2008",
month = "9",
language = "English",
volume = "28",
pages = "3051--3054",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 B",

}

TY - JOUR

T1 - Toxic Encephalopathy and Delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism

AU - Müller, J.

AU - Kralovánszky, Judit

AU - Adleff, Vilmos

AU - Pap, Éva

AU - Németh, Krisztina

AU - Komlósi, Viktor

AU - Kovács, Gábor

PY - 2008/9

Y1 - 2008/9

N2 - Background: High-dose methotrexate (HD-MTX) is one of the most important agents in the therapy of osteosarcoma (OSC). Acute and delayed toxicities still constitute clinical problems. Methylenetetrahydrofolate reductase (MTHFR) has a key role in the folate cycle. In case of homozygosity of the 677C-→T polymorphism, treatment with antimetabolites, such as MTX, can cause additional toxicity. Case Report: In the present work, we describe the case of a 10-year-old boy with OSC. After the first HD-MTX infusion (12 g/m2/6 h) acute neurological disturbances were detected followed by severe hepatotoxicity. Plasma concentrations of MTX and 7-OH-MTX showed delayed clearance. Calcium folinate was administered to the patient until +186 hours. Tha patient was homozygous for the 677 polymorphism and wild-type for the 1298 polymorphism of the MTHFR gene. Conclusion: We hypothesize that MTX toxicity can be explained by the association between homozygosity of the MTHFR C677T polymorphism causing disturbances in the folate status and thus an enhanced vulnerability of the central nervous system to antimetabolites and to the prolonged MTX exposure due to delayed MTX clearance.

AB - Background: High-dose methotrexate (HD-MTX) is one of the most important agents in the therapy of osteosarcoma (OSC). Acute and delayed toxicities still constitute clinical problems. Methylenetetrahydrofolate reductase (MTHFR) has a key role in the folate cycle. In case of homozygosity of the 677C-→T polymorphism, treatment with antimetabolites, such as MTX, can cause additional toxicity. Case Report: In the present work, we describe the case of a 10-year-old boy with OSC. After the first HD-MTX infusion (12 g/m2/6 h) acute neurological disturbances were detected followed by severe hepatotoxicity. Plasma concentrations of MTX and 7-OH-MTX showed delayed clearance. Calcium folinate was administered to the patient until +186 hours. Tha patient was homozygous for the 677 polymorphism and wild-type for the 1298 polymorphism of the MTHFR gene. Conclusion: We hypothesize that MTX toxicity can be explained by the association between homozygosity of the MTHFR C677T polymorphism causing disturbances in the folate status and thus an enhanced vulnerability of the central nervous system to antimetabolites and to the prolonged MTX exposure due to delayed MTX clearance.

KW - Methotrexate

KW - MTHFR

KW - Osteosarcoma

KW - Polymorphism

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=55749103402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55749103402&partnerID=8YFLogxK

M3 - Article

C2 - 19031955

AN - SCOPUS:55749103402

VL - 28

SP - 3051

EP - 3054

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 B

ER -